OPEN END TURBO CALL-OPTIONSSCHEIN MIT SL - BAVARIAN NORDIC | Market Closed - Deutsche Boerse AG 08:23:04 10/05/2024 pm IST | ||
| 7.62 EUR | +0.53% |
|
| Current month | +18.44% | ||
| 1 month | +21.86% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BAVARIAN NORDIC A/S
Latest news about BAVARIAN NORDIC A/S
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/24/10 | 7.62 | +0.53% | 0 |
| 09/24/09 | 7.58 | +0.40% | 0 |
| 08/24/08 | 7.55 | +1.07% | 0 |
| 07/24/07 | 7.47 | +5.21% | 0 |
| 06/24/06 | 7.1 | +7.09% | 0 |
Delayed Quote Deutsche Boerse AG
Last update May 10, 2024 at 08:23 pm IST
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | BAVARIAN NORDIC A/S |
| Issuer | 
Société Générale
|
| WKN | SW1F44 |
| ISIN | DE000SW1F448 |
| Date issued | 25/07/2023 |
| Strike | 106 kr |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 6.69 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 10.94 € |
|---|---|
| Lowest since issue | 3.26 € |
Company Profile
Bavarian Nordic A/S specializes in the development, manufacturing and commercialization of cancer immunotherapies and vaccines for the prevention and treatment of infectious diseases.
Net sales by revenue source are divided between sales of products (97.8%) and services (2.2%).
Net sales are distributed geographically as follows: the United States (36.5%), Canada (22%), France (10.5%), Germany (10.1%), Spain (6.1%), Australia (4.8%), Switzerland ( 1.5%), Sweden (1%), Chile (0.9%), Taiwan (0.8%), the United Kingdom (0.6%), Hong Kong (0.2%), Saudi Arabia (0.1%), and others (4.9%).
Sector
-
Consensus: Bavarian Nordic A/S
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
162.9
DKK
Average target price
262
DKK
Spread / Average Target
+60.83%
- Stock Market
- Certificates
- Certificat